In the present study, the efficacy of treatment and incidence of side effects were evaluated during and after alternating liver chemoembolization treatments with irinotecan-loaded microspheres as first-line treatment together with FOLFIRI systemic chemotherapy, in patients with KRAS, NRAS and BRAF oncogene mutations and inoperable liver metastases from colorectal cancer (CRC-LM). This evidence concerns the gene BRAF and colorectal carcinoma.